SEATTLE - Sana Biotechnology, Inc. (NASDAQ:SANA), a biotech firm specializing in engineered cell therapies, has initiated a public offering of $125 million of its common stock, the company disclosed today. Sana also plans to offer the underwriters an option to purchase additional shares worth up to $18.75 million within a 30-day period.
The offering's completion is contingent on market conditions and other factors, and there is no certainty regarding the timing or the final terms. Morgan Stanley (NYSE:MS), J.P. Morgan, Goldman Sachs & Co (NYSE:GS). LLC, and BofA Securities are serving as the joint book-running managers for the offering.
This move is made under a previously filed and SEC-effective Registration Statement on Form S-3, including a base prospectus. Sana will file a preliminary prospectus supplement with details about the offering. Interested parties can access these documents through the SEC's website or directly from the managing banks.
Sana Biotechnology, with operations across Seattle, Cambridge, South San Francisco, and Rochester, focuses on developing cell-based treatments for various diseases.
The announcement includes forward-looking statements regarding the proposed offering, such as its completion, timing, and size, along with the potential additional share option for underwriters. These statements are subject to market risks, economic conditions, and other uncertainties.
The company has not committed to a specific offering timeline and will not update the forward-looking statements unless new information arises or future events necessitate such actions. This press release is based on a statement from Sana Biotechnology and does not constitute an offer to sell or a solicitation of an offer to buy any securities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.